Vietnam market overview 2q2014 USD

VIETNAM MARKET OVERVIEW 2Q - 2014 Agenda slide • Market Overview • Survey Market Top Lines • Leading Corporations • Leading Products • New Products MAT Therapy Classes Level Performance 2Q 14 Survey Market: US$ 2,432 mill (+5%) M - MUSC ULOSKELETAL SYSTEM (G:10% EI: 105) 5.5% K - HOSPITAL SOLUTIONS (G:5% EI: 101) 4.5% V - VARIOUS (G:6% G - G.U.SYSTEM & SEX HORMONES (G:4% EI: EI: 102) 100) 4.1% 3.8% D DERMATOLOGIC ALS (G:13% EI: 108) 3.6% R - RESPIRATORY SYSTEM (G:14% EI: 109) 6.0% B - BLOOD + B.FORMING ORGANS (G:1% EI: 97) 3.4% S - SENSORY ORGANS (G:23% EI: 117) 2.1% N - NERVOUS SYSTEM (G:6% EI: 101) 6.6% LANTINEOPLAST+IMMU NOMODUL (G:14% EI: 109) 6.8% C - C ARDIOVASC ULAR SYSTEM (G:5% EI: 101) 11.2% A - ALIMENTARY T.& METABOLISM (G:3% EI: 99) 19.5% J - SYSTEMIC ANTIINFEC TIVES (G:-3% EI: 92) 20.9% H - SYSTEMIC HORMONES (G:5% EI: 101) 1.4% T - DIAGNOSTIC AGENTS (G:9% EI: 104) 0.6% P - PARASITOLOGY (G:2% EI: 97) 0.2% MAT Regions Performance 2Q 14 Survey Market: US$ 2,432 mill (+5%) CAN THO (G:9%; E:104) 3.9% HANOI (G:9%; E:104) 18.9% DA NANG (G:14%; E:109) 2.9% HCMC (G:1%; E:96) 31.9% ALL OTHER (G:4%; E:100) 39.8% HAI PHONG (G:14%; E:109) 2.6% MAT Regions Performance 2Q 14 Pharmacy Hospital Survey Market: US$ 886 mill (+8%) Survey Market: US$ 1,546 mill (+3%) CAN THO (G:4%; E:101) 2.5% CAN THO (G:12%; E:104) 6.4% HANOI (G:5%; E:98) 19.3% HCMC (G:4%; E:96) 30.3% ALL OTHER (G:10%; E:102) 34.4% DA NANG (G:21%; E:112) 5.3% HAI PHONG (G:12%; E:104) 4.3% HCMC (G:1%; E:97) 32.8% HANOI (G:11%; E:108) 18.7% ALL OTHER (G:2%; E:99) 42.9% HAI PHONG (G:16%; E:113) 1.6% DA NANG (G:3%; E:100) 1.5% 2Q 14 1Q 14 2.68 2.54 2.62 2.72 2.59 2Q 13 4Q 13 2.61 1Q 13 2.76 2.61 4Q 12 3Q 13 2.56 3Q 12 2.44 2.37 1Q 12 2Q 12 2.37 4Q 11 2.21 2Q 11 2.33 2.22 1Q 11 3Q 11 2.22 2.41 4Q 10 2.21 3Q 10 2Q 10 2.13 1Q 10 2.21 4Q 09 3Q 09 Survey Market Trend W eig h ted Avg P rice V alu e M illion US $ P ack M illion 670 640 610 580 550 520 490 460 430 400 370 340 310 280 250 220 190 160 130 100 70 40 10 MAT Import Vs Local 2Q 14 Volume (mill UNIT) Value (mill US$) 2,432 1,546 35% +6% 31% +3% +4% 65% +3% 69% Total Hospital 886 43% +11% +6% 57% Pharmacy Local Imported 19,712 9,103 10,609 +6% 75% +7% 77% +5% 74% +1% 25% +1% 23% +0% 26% Total Hospital Pharmacy MAT Branded Vs Generic 2Q 14 Volume (mill UNIT) Value (mill US$) 2,432 1,546 886 +3% 74% +1% 75% +7% 72% +10% 26% +11% 25% +9% 28% Total Hospital Pharmacy 19,712 9,103 10,609 +5% 92% +6% 94% +3% 91% +1% 8% -8% 6% +7% 9% Hospital Pharmacy Generic Branded Total Agenda slide • Market Overview • Survey Market Top Lines • Leading Corporations • Leading Products • New Products MAT Leading Corporations 2Q 14 Survey Market: US$ 2,432 mill (+5%) Managed Products: US$ 2,424 mill (+5%) % MAT SPLY QTR Million US$ 1 SANOFI 2 GSK NOVARTIS DHG PHARMA ASTRAZENECA ROCHE 7 MSD PFIZER 9 SERVIER 10 16 12 ±% BOEH INGEL 80.3 0.00 46.2 0.06 44.7 0.19 37.3 32.9 3.5% 0% 96 0.42 567 -4% 10% 105 7.42 277 -8% 2.3% 8% 104 4.27 131 -1% 54.7 2.3% -7% 89 -4.13 1,076 -1% 2.2% 14% 109 6.56 64 0% 2.1% 32% 126 12.22 18 14% 1.9% 9% 104 3.87 101 0% 1.8% 3% 98 1.24 90 16% 1.5% -7% 89 -2.79 209 -12% 50.5 0.29 ±% 3.3% 52.9 0.02 UNIT 55.1 0.13 0.35 V/Increase (mill US$) (mill Unit) UNIT 84.9 1.12 EI 1.4% 20% 115 5.55 109 15% 31.2 1.3% 13% 108 3.62 59 -5% 30.8 1.3% 12% 107 3.38 393 18% 29.6 1.2% -1% 94 -0.40 520 -12% 29.4 1.2% -14% 82 -4.75 47 -13% 0.00 11 14 10 BAYER H/C 12 15 14 BIDIPHAR 13 12 17 TRAPHACO 14 10 11 FRESENIUS BIDIPHAR 15 19 16 DOMESCO 29.1 1.2% 20% 115 4.95 677 19% 29.0 1.2% 12% 107 3.14 73 15% 1.1% 0% 95 -0.11 450 -9% 1.0% 25% 120 5.10 1% 23.6 1.0% 18% 113 3.65 48 32% 23.4 1.0% 7% 103 1.59 16% 16 18 13 J&J 17 13 18 STADA 18 23 19 BAXTER 19 24 22 ST.PAUL BRANDS 20 21 15 HOSPIRA 0.05 0.00 0.03 0.00 0.00 27.9 25.2 Leading Therapy Classes Level III Rank Corporation Leading Million US$ CEPHALOSPORINS & COMBS - J01D ANTIULCERANTS - A02B BROAD SPECTRUM PENICILLIN - J01C NON-NARCOTIC ANALGESICS - N02B 221.9 GSK Share in TC3s 7.8% Product Leading Share in TC3s ZINNAT - GSK 5.9% ASTRAZENECA 13.4% NEXIUM - ASTRAZENECA 11.8% GSK 26.8% AUGMENTIN - GSK 24.7% 56.1 BMS 17.9% EFFERALGAN - BMS 10.9% OTH MUSCULO-SKELETAL PRDS - M05X 56.0 ST.PAUL BRANDS 14.9% JEX - ST.PAUL BRANDS 14.8% CEREB.+PERIPHE.VASOTHERAP - C04A 51.9 TRAPHACO 14.6% HOAT HUYET D/NAO - TRAPHACO 10.8% HEPAT PROTECT-LIPOTROPICS - A05B 51.8 TRAPHACO 12.0% BOGANIC - TRAPHACO 11.8% OTH B-LACTAM EX PEN,CEPH - J01P MSD 28.3% TIENAM - MSD 23.5% ALL OTH.THERAPEUTIC PRDS - V03X 42.1 JSC SCIENTIFIC 10 FLUOROQUINOLONES - J01G 39.0 BAYER H/C 21.0% CIPROBAY - BAYER H/C 15.4% 11 ANTIRHEUMATIC NON-STEROID - M01A 37.8 BOEH INGEL 12.8% MOBIC - BOEH INGEL 12.8% 12 OTHER DERMATOLOGICALS - D11A 36.2 HOA THIEN PHU 24.1% SAC NGOC KHANG - HOA THIEN PHU 21.2% 13 CHOLEST&TRIGLY.REGULATOR - C10A 34.9 ASTRAZENECA 13.3% CRESTOR - ASTRAZENECA 13.3% 14 CALCIUM - A12A 34.5 SANOFI 23.4% CALCIUM CORBIERE - SANOFI 23.3% 15 VINCA ALKALOIDS - L01C 33.2 HOSPIRA 34.6% ANZATAX - HOSPIRA 22.8% 16 MACROLIDES & SIMILAR TYPE - J01F 31.1 PFIZER 14.6% ZITHROMAX - PFIZER 10.4% 17 PROTEIN SOLUTIONS - K03B 29.5 BAXTER 26.3% HUMAN ALBUMIN - BAXTER 26.3% 18 TONICS - A13A 29.4 ST.PAUL BRANDS 16.7% ALIPAS - ST.PAUL BRANDS 16.7% 19 ANTI-INFLAMMATORY ENZYME - V03H 27.8 SANOFI 29.4% ALPHACHYMOTRYPSIN - SANOFI 29.4% 20 NOOTROPICS - N06D 25.4 ITALFARMACO 22.3% GLIATILIN - ITALFARMACO 78.9 71.0 46.7 5.8% REAMBERIN - JSC SCIENTIFIC 5.8% 22.3% MAT Leading Products Survey Market: US$ 2,432 mill (+5%) 2Q 14 Managed Products: US$ 2,424 mill (+5%) % MAT SPLY QTR ±% EI V/Increase Million US$ 1 AUGMENTIN - GSK 2 ZINNAT - GSK 3 MERONEM - ASTRAZENECA 10.97 TIENAM - MSD 10.97 4 5 DIANEAL LOW CALCI - BAXTER 6 DIAMICRON - SERVIER 7 NEXIUM - ASTRAZENECA 8 CEREBROLYSIN - EVER NEURO PHARMA 9 13 10 10 16 11 11 12 10.54 9.60 9.28 8.90 ±% (mill US$) (mill Unit) UNIT 17.55 13.17 UNIT 0.72% 19% 114 2.78 25.77 17% 0.54% 18% 113 2.05 15.98 22% 0.45% 23% 118 2.08 0.33 19% 0.45% 7% 102 0.74 0.68 5% 0.43% 0% 96 0.00 2.99 0% 0.39% -6% 90 -0.62 64.40 -11% 0.38% 17% 112 1.37 5.91 13% 0.37% 13% 108 1.04 1.98 15% 0.35% 62% 155 3.27 0.15 72% MIXTARD 30 - NOVO NORDISK A/S 8.32 0.34% 19% 114 1.33 1.05 32% 19 JEX - ST.PAUL BRANDS 8.30 0.34% 73% 165 3.50 19.35 75% 12 14 COVERSYL - SERVIER 8.28 0.34% 0% 95 -0.02 32.61 0% 13 13 28 ALPHACHYMOTRYPSIN - SANOFI 8.19 0.34% 24% 119 1.61 107.75 26% 14 14 11 CALCIUM CORBIERE - SANOFI 8.06 0.33% 2% 97 0.15 44.60 -1% 15 15 23 HUMAN ALBUMIN - BAXTER 7.76 0.32% 62% 155 2.98 0.19 64% 16 16 15 SAC NGOC KHANG - HOA THIEN PHU 7.67 0.32% 129% 218 4.32 62.39 134% 17 17 12 PLAVIX - SANOFI 7.62 0.31% 12% 107 0.83 7.75 15% 18 18 ANZATAX - HOSPIRA 7.57 0.31% 5% 101 0.39 0.05 16% 19 19 27 HAGINAT - DHG PHARMA 6.55 0.27% -14% 82 -1.09 15.74 -4% 20 20 34 BISEKO - BIOTEST PHARMA 6.33 0.26% 49% 143 2.09 0.15 52% 8.53 TARCEVA - ROCHE Leading Products Survey Market: US$ 803 mill (+9%) 3 MAT 2Q 14 Managed Products: US$ 802 mill (+9%) % MAT SPLY QTR OTC ±% EI Million US$ 8.06 CALCIUM CORBIERE - SANOFI 7.67 SAC NGOC KHANG - HOA THIEN PHU UNIT ±% (mill US$) (mill Unit) UNIT 8.30 JEX - ST.PAUL BRANDS V/Increase 1.03% 73% 160 3.50 19.3 75% 1.00% 2% 94 0.15 44.6 -1% 0.96% 129% 211 4.32 62.4 134% 0.76% 12% 103 0.64 50.5 13% 4 EFFERALGAN - BMS 6.12 5 BOGANIC - TRAPHACO 6.09 0.76% -21% 72 -1.66 139.4 -21% 6 TANAKAN - IPSEN 6.01 9 12 0.75% -2% 90 -0.12 32.3 -2% HOAT HUYET NHATNHA - NHAT NHAT 5.83 0.73% 4% 96 0.23 54.1 -4% ENTEROGERMINA - SANOFI 5.70 0.71% 34% 123 1.44 20.8 34% 5.58 0.69% 13% 104 0.64 183.9 2% 0.65% -27% 68 -1.90 11.7 -25% HOAT HUYET D/NAO - TRAPHACO 5.20 10 10 11 ANGELA WOMENS GINS - ST.PAUL BRANDS 11 11 14 ALIPAS - ST.PAUL BRANDS 4.91 0.61% -33% 62 -2.43 5.6 -32% 12 12 10 MARVELON - MSD 4.84 0.60% 26% 116 0.99 40.6 29% 13 13 HAPACOL - DHG PHARMA 4.79 14 14 16 0.60% 26% 116 0.99 121.9 6% PHARMATON - BOEH INGEL 4.53 0.56% 6% 98 0.25 22.2 6% 0.56% -21% 72 -1.23 32.0 -21% 0.55% -10% 83 -0.48 102.8 -15% 0.53% 78% 164 1.87 1.5 74% 0.49% 3% 95 0.12 82.6 6% 15 15 13 DAFLON - SERVIER 4.50 16 16 29 PANADOL EXTRA - GSK 4.44 17 17 15 PROSPAN - ENGELHARD ARZNEIMI 18 18 17 SALONPAS - HISAMITSU 19 19 27 STREPSILS - RECKITT BENCKISER 3.57 0.44% 1% 93 0.02 66.0 -3% 20 20 18 PHOSPHALUGEL - BOEH INGEL 3.52 0.44% 7% 99 0.23 21.5 8% 4.29 3.97 Ethical MAT 2Q 14 Leading Products Survey Market: US$ 1,629 mill (+3%) Managed Products: US$ 1,622 mill (+3%) % MAT SPLY QTR 115 2.78 25.77 17% 0.81% 18% 115 2.05 15.98 22% 0.67% 23% 120 2.08 0.33 19% 0.67% 7% 104 0.74 0.68 5% 0.65% 0% 97 0.00 2.99 0% 0.59% -6% 91 -0.62 64.40 -11% 0.57% 17% 114 1.37 5.91 13% 0.55% 13% 110 1.04 1.98 15% 8.53 0.52% 62% 158 3.27 0.15 72% 0.51% 19% 116 1.33 1.05 32% -0.02 32.61 0% 2 ZINNAT - GSK 3 MERONEM - ASTRAZENECA 10.97 TIENAM - MSD 10.97 DIANEAL LOW CALCI - BAXTER 6 DIAMICRON - SERVIER 7 NEXIUM - ASTRAZENECA 8 CEREBROLYSIN - EVER NEURO PHARMA 9 12 13.17 10.54 9.60 9.28 8.90 TARCEVA - ROCHE ±% 19% AUGMENTIN - GSK UNIT 1.08% V/Increase (mill US$) (mill Unit) UNIT 17.55 EI Million US$ ±% 10 10 14 MIXTARD 30 - NOVO NORDISK A/S 8.32 11 11 13 COVERSYL - SERVIER 8.28 0.51% 0% 97 12 12 23 ALPHACHYMOTRYPSIN - SANOFI 8.19 0.50% 24% 121 1.61 107.75 26% 13 13 19 HUMAN ALBUMIN - BAXTER 7.76 0.48% 62% 158 2.98 0.19 64% 14 14 11 PLAVIX - SANOFI 7.62 0.47% 12% 109 0.83 7.75 15% 15 15 ANZATAX - HOSPIRA 7.57 0.46% 5% 102 0.39 0.05 16% 16 16 22 HAGINAT - DHG PHARMA 6.55 0.40% -14% 83 -1.09 15.74 -4% 17 17 27 BISEKO - BIOTEST PHARMA 6.33 0.39% 49% 145 2.09 0.15 52% 18 18 28 CONCOR - MERCK SERONO 6.26 0.38% 5% 102 0.28 40.11 6% 19 19 21 DBL OXALIPLATIN - HOSPIRA 6.25 0.38% 5% 102 0.32 0.05 55% 20 20 15 CIPROBAY - BAYER H/C 6.01 0.37% 46% 142 1.90 3.64 26% Leading Products Pharmacy MAT 2Q 14 Managed Products: US$ 883 mill (+8%) Survey Market: US$ 886 mill (+8%) % MAT SPLY QTR ±% EI V/Increase Million US$ 1 AUGMENTIN - GSK 2 JEX - ST.PAUL BRANDS 3 SAC NGOC KHANG - HOA THIEN PHU 4 ZINNAT - GSK 5 CALCIUM CORBIERE - SANOFI 6 ALPHACHYMOTRYPSIN - SANOFI 7 15 8 9 14 10 10 11 11 12 1.16% 9% 102 0.89 16.3 13% 0.90% 73% 161 3.37 18.6 75% 0.86% 129% 213 4.29 61.8 135% 7.18 0.81% 12% 104 0.75 9.0 16% 7.18 0.81% 10% 102 0.67 39.4 7% 0.74% 42% 132 1.94 85.7 44% 0.60% 1% 94 0.06 49.8 -6% 7.98 7.61 6.54 5.35 ±% (mill US$) (mill Unit) UNIT 10.32 HOAT HUYET NHATNHA - NHAT NHAT UNIT EFFERALGAN - BMS 5.16 0.58% 17% 108 0.73 42.4 18% ANGELA WOMENS GINS - ST.PAUL BRANDS 5.03 0.57% -28% 67 -1.93 11.4 -26% TANAKAN - IPSEN 4.83 0.54% 7% 99 0.31 26.0 9% 16 ALIPAS - ST.PAUL BRANDS 4.74 0.54% -34% 61 -2.45 5.4 -33% 12 13 DIAMICRON - SERVIER 4.72 0.53% -2% 91 -0.11 32.7 -9% 13 13 10 MARVELON - MSD 4.65 0.53% 25% 116 0.94 39.1 28% 14 14 17 PHARMATON - BOEH INGEL 4.45 0.50% 6% 98 0.24 21.8 6% 15 15 ENTEROGERMINA - SANOFI 4.37 0.49% 28% 119 0.95 16.0 28% 16 16 35 PANADOL EXTRA - GSK 4.23 0.48% -10% 84 -0.45 98.1 -15% 17 17 12 GLUCOPHAGE - MERCK SERONO 0.45% 20% 112 0.68 33.4 22% 18 18 11 HOAT HUYET D/NAO - TRAPHACO 3.73 0.42% 36% 127 1.00 120.1 17% 19 19 20 SALONPAS - HISAMITSU 3.69 0.42% 2% 94 0.06 76.4 4% 20 20 18 CEREBROLYSIN - EVER NEURO PHARMA 3.63 0.41% 16% 108 0.50 0.8 19% 4.00 Leading Products Survey Market: US$ 1,546 mill (+3%) Hospital % ±% EI Million US$ 1 MERONEM - ASTRAZENECA 2 TIENAM - MSD 3 DIANEAL LOW CALCI - BAXTER 4 TARCEVA - ROCHE 5 ANZATAX - HOSPIRA 6 AUGMENTIN - GSK 7 18 HUMAN ALBUMIN - BAXTER 8 14 NEXIUM - ASTRAZENECA 9 20 MIXTARD 30 - NOVO NORDISK A/S 10 10 16 BISEKO - BIOTEST PHARMA 11 11 10 DBL OXALIPLATIN - HOSPIRA 12 12 15 ZINNAT - GSK 13 13 13 MABTHERA - ROCHE 14 14 HUMAN ALBUMIN - HUMAN BIOPLAZMA 15 15 26 SEVORANE - ABBVIE 16 16 24 HAGINAT - DHG PHARMA 17 17 18 18 19 19 20 20 103 2Q 14 Managed Products: US$ 1,541 mill (+3%) MAT SPLY QTR MAT V/Increase UNIT ±% (mill US$) (mill Unit) UNIT 0.70% 24% 121 2.11 0.33 19% 0.70% 8% 105 0.77 0.67 5% 0.68% 0% 97 0.00 2.99 0% 0.54% 62% 157 3.18 0.15 72% 0.49% 5% 102 0.39 0.05 16% 7.24 0.47% 35% 131 1.89 9.42 26% 7.14 0.46% 53% 149 2.49 0.17 54% 0.44% 24% 120 1.30 3.35 18% 0.43% 21% 118 1.16 0.87 35% 6.29 0.41% 50% 145 2.09 0.15 52% 6.24 0.40% 5% 102 0.31 0.05 55% 0.39% 28% 124 1.30 7.02 31% 5.79 0.37% -1% 96 -0.06 0.00 2% 5.74 0.37% 20% 116 0.95 0.12 41% 0.36% 31% 127 1.30 0.03 18% 5.32 0.34% -16% 82 -0.99 12.53 -3% GLIATILIN - ITALFARMACO 5.30 0.34% 2% 99 0.08 1.50 0% 29 NANOKINE - NANOGEN PHARMA 5.27 0.34% 189% 280 3.44 0.48 233.8% 11 CEREBROLYSIN - EVER NEURO PHARMA 5.27 0.34% 11% 108 0.54 1.15 11% INFANRIX HEXA - GSK 5.25 0.34% 31% 127 1.24 0.18 35% 10.88 10.82 10.54 8.31 7.57 6.77 6.59 5.99 5.49 Agenda slide • Market Overview • Survey Market Top Lines • Leading Corporations • Leading Products • New Products 26 MAT New Products 2Q 14 Size: US$ 72.9 mill & Share: 3.0% Definition of New Products: •New brands/form/packaging •Available in the market •Within year (since 2Q2013) New brands 2.4% - US$ 58.4 mill New Form 0.6% - US$ 14.3 mill 27 MAT New Products 2Q 14 Import Vs Local Volume (mill UNIT) Value (mill US$) 72.9 45% 47.4 25.5 213.7 179.6 77% 77% 77% 23% 23% 23% Total Hospital Pharmacy 38% 58% 55% 393.3 62% Local Imported 42% Total 28 Hospital Pharmacy MAT New Products 2Q 14 Size: US$ 72.9 mill & Share: 3.0% V - VARIOUS 6.2% G - G.U.SYSTEM & SEX N - NERVOUS SYSTEM HORMONES 4.2% 5.7% B - BLOOD + B.FORMING ORGANS 4.1% D - DERMATOLOGICALS 3.9% M - MUSCULO-SKELETAL SYSTEM 6.3% R - RESPIRATORY SYSTEM 3.6% K - HOSPITAL SOLUTIONS 2.0% C - CARDIOVASCULAR SYSTEM 9.9% LANTINEOPLAST+IMMUNOM ODUL 10.7% S - SENSORY ORGANS 1.0% A - ALIMENTARY T.& J - SYSTEMIC ANTI- METABOLISM INFECTIVES 20.7% 20.7% H - SYSTEMIC HORMONES 0.9% T - DIAGNOSTIC AGENTS 0.1% P - PARASITOLOGY 0.0% 29 MAT New Products 2Q 14 Size: US$ 77.4 mill & Share: 3.2% Leading product form Corporation TC4 FAZ BTTL 30 CAPS (IO R) ST.PAUL BRANDS C10B00 1,879 CARMERO 1.00 G VIAL DRY IV (L ER) EUVIPHARM J01P02 1,867 BIO-ACIMIN GOLD G 30 SAC GRAN (L O R) MELIPHAR-ME LINH A07F00 NEXIUM 40 MG BOX 14 MUPS TAB (I ER) ASTRAZENECA A02B02 1,625 DA HUONG MU/-TD-AL 100 ML L/SP VAG (L O R) NATA-HOA LINH G01D00 1,616 ALFALOG BOX 100 TAB F.C (IO R) RPG LIFE SCIENCES A16A00 1,320 B02D01 1,049 CEFTIZOXIME 1.00 G 10 VIAL DRY (I ER) SWISS PHARM-TAIWAN J01D02 990 ZIDIMBIOTIC 1000 MG 10 VIAL DRY (L ER) TENAMYD J01D02 980 ESSENCICAPS 300 MG BOX 50 CAPS (IO R) MINSKINTERCAPS A16A00 959 CAPSY 500 MG BOX 10 TAB F.C (I ER) INTAS L01B00 939 CUMARGOLD BOX 30 SOFTCAP (L O R) CVI PHARMA V03X00 835 VIMOTRAM 1.00 G /0.5 VIAL DRY (L ER) VIET TRUNG-VCP J01C02 818 JOBEZOL 40 MG ML VIAL DRY+SL (I ER) MEDEX A02B02 SUNOXIPLAT 50 MG VIAL DRY INF (I ER) SUN PHARMA L01F00 XUONG KHOP NHATNHA BOX 20 TAB F.C (L O R) NHAT NHAT M05X00 GAMMA I.V 2.5 G 50 ML INF (I ER) MEGA PRODUCT J06C00 CEFTAZIDIME (AV0) 1.00 G VIAL DRY (L ER) AMVIPHARM-AM VI J01D02 MELOFLAM 15 MG BOX 20 TAB (I ER) EGIS M01A01 FDP MEDLAC G 50 ML VIAL INF+SL (L ER) MEDLAC PHARMA C06A00 30 755 671 634 588 545 515 499 ‘000 US$ HAEMOCTIN SDH 500 IU 10 ML VIAL DRY+SL (I ER) BIOTEST PHARMA 1,782 MAT New Brands 2Q 14 Size: US$ 58.4 mill & Share: 2.4% Corporation TC4 FAZ BTTL 30 CAPS (IO R) ST.PAUL BRANDS C10B00 BIO-ACIMIN GOLD G 30 SAC GRAN (L O R) MELIPHAR-ME LINH A07F00 ALFALOG BOX 100 TAB F.C (IO R) RPG LIFE SCIENCES A16A00 HAEMOCTIN SDH 500 IU 10 ML VIAL DRY+SL (I ER) BIOTEST PHARMA 1,879 1,782 1,320 B02D01 1,049 CEFTIZOXIME 1.00 G 10 VIAL DRY (I ER) SWISS PHARM-TAIWAN J01D02 990 ZIDIMBIOTIC 1000 MG 10 VIAL DRY (L ER) TENAMYD J01D02 980 ESSENCICAPS 300 MG BOX 50 CAPS (IO R) MINSKINTERCAPS A16A00 959 CAPSY 500 MG BOX 10 TAB F.C (I ER) INTAS L01B00 939 CUMARGOLD BOX 30 SOFTCAP (L O R) CVI PHARMA V03X00 835 VIMOTRAM 1.00 G /0.5 VIAL DRY (L ER) VIET TRUNG-VCP J01C02 818 JOBEZOL 40 MG ML VIAL DRY+SL (I ER) MEDEX A02B02 SUNOXIPLAT 50 MG VIAL DRY INF (I ER) SUN PHARMA L01F00 XUONG KHOP NHATNHA BOX 20 TAB F.C (L O R) NHAT NHAT M05X00 GAMMA I.V 2.5 G 50 ML INF (I ER) MEGA PRODUCT J06C00 CEFTAZIDIME (AV0) 1.00 G VIAL DRY (L ER) AMVIPHARM-AM VI J01D02 MELOFLAM 15 MG BOX 20 TAB (I ER) EGIS M01A01 515 FDP MEDLAC G 50 ML VIAL INF+SL (L ER) MEDLAC PHARMA C06A00 499 NEUPEG MG /ML 1.00 ML SY PREF SC (I ER) INTAS L03A01 452 GREAXIM 1.00 G ML VIAL DRY+SL (I ER) AMVIPHARM-AM VI J01D02 451 BAO XUAN TUOI 50 BOX 30 CAPS (L O R) NAM DUOC G02X09 31 755 671 634 588 545 404 ‘000 US$ Leading product form MAT New Forms 2Q 14 Size: US$ 14.3 mill & Share: 0.6% Leading product form Corporation TC4 CARMERO 1.00 G VIAL DRY IV (L ER) EUVIPHARM J01P02 NEXIUM 40 MG BOX 14 MUPS TAB (I ER) ASTRAZENECA A02B02 1,625 DA HUONG MU/-TD-AL 100 ML L/SP VAG (L O R) NATA-HOA LINH G01D00 1,616 MOTOMIN 500 ML INFUSION (I ER) CCPC K01E01 493 AMOXICILIN (P3B) 1000 MG BOX 100 CAPL F.C (L ER) PHARBACO (TW1) J01C01 489 NEXIUM 20 MG BOX 14 MUPS TAB (I ER) ASTRAZENECA A02B02 LIPIGOLD 20 % 250 ML INF BAG (I ER) JW LIFE SCIENCE K01D01 255 TELFAST 180 MG BOX 10 CAPL HD (L O R) SANOFI R06A00 237 1,867 SALBUTAMOL (RDN) MG /5ML ML 10 AMP INF (I ER) RENAUDIN R03A02 194 ALDAN MG BOX 30 TAB (I ER) POLFARMEX C08A00 194 RECTIOFAR ML 50 LIQ RECTAL (L O R) PHARMEDIC A06A04 192 PRASOCARE 40 MG VIAL DRY IV (I ER) BHARATPARENTERALS A02B02 177 BIFUMAX 750 MG ML VIAL DRY+SL (L ER) BIDIPHAR J01D02 171 PACLITAXEL STRAGEN MG /ML 50 ML VIAL INF (I ER) HAUPT PHARMALIVRON L01C00 151 LOSARTAN STADA 25 MG BOX 30 TAB F.C (L ER) STADA C09C00 145 FAROMEN 1.00 G 20 ML VIAL DRY+SL (I ER) KWALITY J01P02 126 GEMNIL 200 MG VIAL DRY (I ER) VIANEX L01B00 126 AUSTRIOL 250 Y BOX 100 SOFTCAP (L ER) MEBIPHAR-AUSTRAPHA A11C02 121 AMINOACID KABI % 250 ML INFUSION (L ER) FRESENIUS BIDIPHAR K01E01 115 LACBIO PRO 1.00 G 30 SAC PWD (L O R) BIDIPHAR A07F00 32 114 ‘000 US$ 283 Top 10 Corporations Top 10 ® : Top 10 corporations with products officially managed by Vietnam offices SANOFI GSK NOVARTIS DHG PHARMA ASTRAZENECA ROCHE MSD PFIZER SERVIER BOEH INGEL 33 [...]... 31% 127 1.24 0.18 35% 10.88 10.82 10.54 8.31 7.57 6.77 6.59 5.99 5.49 Agenda slide • Market Overview • Survey Market Top Lines • Leading Corporations • Leading Products • New Products 26 MAT New Products 2Q 14 Size: US$ 72.9 mill & Share: 3.0% Definition of New Products: •New brands/form/packaging •Available in the market •Within 1 year (since 2Q2013) New brands 2.4% - US$ 58.4 mill New Form 0.6% -... 37.34 -7.0% 32.89 20.3% 31.20 13.1% 30.80 12.3% 29.58 -1.3% 29.35 -13.9% 29.14 20.5% 28.98 12.2% 27.86 -0.4% 25.17 25.4% 23.59 18.3% 23.36 7.3% -20% -10% 0% 10% 20% 30% 40% Agenda slide • Market Overview • Survey Market Top Lines • Leading Corporations • Leading Products • New Products 18 Top 10 Fastest Growing Therapy Classes Level III Cut-off size: US$ 500,000 Rank ±% 000 US$ Corporation Leading... PWD (L O R) BIDIPHAR A07F00 32 114 ‘000 US$ 283 Top 10 Corporations Top 10 ® : Top 10 corporations with products officially managed by Vietnam offices SANOFI GSK NOVARTIS DHG PHARMA ASTRAZENECA ROCHE MSD PFIZER SERVIER BOEH INGEL 33